



21<sup>st</sup> June 2011

**Fesoterodine (Toviaz®▼) for the treatment of symptoms associated with overactive bladder syndrome**

The New Therapies Subgroup discussed the above drug at a meeting on the 21<sup>st</sup> April 2009 and 21<sup>st</sup> June 2011. The recommendation of this subgroup is as follows:\*

The New Therapies Subgroup of the GMMMG considered the use of fesoterodine (Toviaz®▼) for the treatment of symptoms associated with overactive bladder syndrome.

**The group does routinely recommend fesoterodine and choice of product should follow the NICE CG 171**

NICE clinical guideline 40 states that there is no evidence of clinically important differences in efficacy between anti-muscarinic drugs and therefore the most **cost-effective** option should be used.

Fesoterodine confers no additional advantage over more established therapies and immediate release non-proprietary oxybutynin remains the most cost effective of all available options.

Review date: June 2013

\* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.